Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Braftovi and Mektovi encorafenib and binimetinib Advanced Melanoma Reimburse with clinical criteria and/or conditions Complete
Brenzys Etanercept Rheumatoid arthritis, Ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Breo Ellipta Fluticasone furoate /vilanterol Chronic Obstructive Pulmonary Disease (COPD) List with criteria/condition Complete
Breo Ellipta Fluticasone Furoate and Vilanterol (as trifenatate) Asthma List with clinical criteria and/or conditions Complete
Breo Ellipta fluticasone furoate/vilanterol COPD Withdrawn
Breo Ellipta fluticasone furoate/vilanterol Asthma Withdrawn
Breyanzi lisocabtagene maraleucel Relapsed or refractory large B-cell lymphoma Reimburse with clinical criteria and/or conditions Complete
Breyanzi lisocabtagene maraleucel Relapsed or refractory large B-cell lymphoma Reimburse with clinical criteria and/or conditions Active
Breztri Aerosphere budesonide/ glycopyrronium /formoterol fumarate chronic obstructive pulmonary disease (COPD) Reimburse with clinical criteria and/or conditions Complete
Brilinta ticagrelor Prevention of atherothrombotic events with history of myocardial infarction Reimburse with clinical criteria and/or conditions Complete